Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Combination With Pembrolizumab

NCT04418219 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT04418219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04418219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Combination With Pembrolizumab
Lead sponsor
Thomas Jefferson University
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 21, 2020
Completion date
January 1, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, metastatic breast carcinoma, prognostic stage iv breast cancer ajcc v8, recurrent breast carcinoma, refractory breast carcinoma